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Abstract
Cardiovascular disease (CVD) is increasingly recognised as a complication of childhood chronic kidney disease (CKD) even in
the absence of diabetes and hypertension. We hypothesized that an alteration in angiopoietin-1 and -2, growth factors
which regulate endothelial and vascular function could be involved. We report that the endothelial survival factor,
angiopoietin-1 is low in children with pre-dialysis CKD whereas the pro-inflammatory angiopoietin-2 is elevated in children
on dialysis. In dialysis patients, angiopoietin-2 positively correlated with time on dialysis, systolic blood pressure, and carotid
artery intima media thickness. Elevated angiopoietin-2 levels in dialysis versus pre-dialysis CKD patients were also associated
with an anti-angiogenic (high soluble VEGFR-1 and low VEGF-A) and pro-inflammatory (high urate, E-selectin, P-selectin and
VCAM-1) milieu. Ang-2 was immunodetected in arterial biopsy samples whilst the expression of VEGF-A was significantly
downregulated in dialysis patients. Serum urate correlated with angiopoietin-2 levels in dialysis patients and addition of uric
acid was able to induce rapid release of angiopoietin-2 from cultured endothelial cells. Thus, angiopoietin-2 is a marker for
cardiovascular disease in children on chronic dialysis and may act as an anti-angiogenic and pro-inflammatory effector in
this context. The possibility that the release of angiopoietin-2 from endothelia is mediated by urate should be explored
further.
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Introduction
Children with chronic kidney disease (CKD) develop early onset
cardiovascular disease (CVD). [1] Manifestations of CVD in
childhood CKD include arterial stiffening [2] and calcification, [3]
premature atherosclerosis, [4] and left ventricular hypertrophy. [5]
Over time, CKD developing in children is associated with
increased cardiovascular mortality that markedly accelerates once
dialysis is initiated. [6,7]
One of the earliest signs of CVD in individuals with CKD is
endothelial damage and dysfunction, [8] and this has been shown
even in children with pre-dialysis CKD. [9] In this context,
potential causes of endothelial damage and aberrant repair are
disturbances in growth factors involved in the formation of
vascular networks. [10] Angiopoietin-1 (Ang-1) binds and activates
the Tie-2 receptor on endothelia where it promotes cell survival
and decreases vascular permeability. [11] As such, Ang-1 is usually
considered beneficial for endothelial cell function. In contrast,
Ang-2 is released from Weibel-Palade bodies by various stimuli
[12,13] and acts as an antagonist of Ang-1. [14] Ang-2 has pro-
inflammatory actions [15,16] and can also promote or retard
angiogenesis dependent on the ambient levels of vascular
endothelial growth factor-A (VEGF-A). [14] Other evidence exists
that, in certain circumstances, Ang-2 may have biological effects,
independent of the antagonism of Ang-1. [17,18]
Elevated circulating Ang-2 has been reported in adults with
CKD. David and colleagues [19] found an inverse relationship
between circulating Ang-2 levels and glomerular filtration rate in
adults with CKD. Two other studies reported that Ang-2 levels
were elevated in adults on hemodialysis (HD) or peritoneal dialysis
(PD) compared with healthy controls. [20,21] In one of these
studies Ang-2 correlated with scoring for coronary and peripheral
arterial disease. [20] In the other study, Ang-2 correlated with
cholesterol, high-sensitive C-reactive protein and osteoprotegerin
and was an independent predictor of mortality. [21]
To date, no clinical studies have examined angiopoietins in
childhood CKD, despite the latter having similar cardiovascular
complications as adults with CKD, but at a proportionately earlier
age. [1] These effects are more likely to be directly attributed to
the uremic milieu because children seldom have diabetes or
dyslipidaemia, uncontrolled hypertension or are smokers which
themselves predispose to CVD. We hypothesized that an
imbalance of angiopoietin vascular growth factors, which would
be detrimental to endothelial structure and function, might be
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present in children with CKD. Specifically, we predicted that
childhood CKD would be associated with elevated Ang-2 and that
it would correlate with inflammatory markers.
Materials and Methods
Patient cohort
Informed written consent was obtained from the next of kin,
caretakers, or guardians on the behalf of the minors/children
participants, and children also gave their assent where appropri-
ate. The study was approved by the Great Ormond Street
Hospital and UCL Institute of Child Health research ethics
committee. From January to December 2010, 20 children in pre-
dialysis CKD stages 4-5 and 30 on dialysis (14 PD, 16 on HD)
were recruited from Great Ormond Street Hospital. Primary
diagnoses included renal dysplasia (n = 20), posterior urethral
valves (n = 9), focal segmental glomerulosclerosis (n = 6), nephro-
nophthisis (n = 4), cortical necrosis (n = 3), and 2 each with
autosomal recessive polycystic kidney disease, congenital nephrotic
syndrome, bilateral Wilms’ tumors and unknown causes. None of
the children had diabetes and none were smokers. Children with
underlying inflammatory disorders, such as glomerulonephritis
and vasculitides were excluded. Patients were compared with
healthy age- and gender- matched children who formed part of a
contemporaneous study and are previously described. [22]
Clinical, biochemical and vascular parameters
All measures were taken at the same clinical visit; pre a mid-
week session of HD or at clinic review for pre-dialysis CKD and
PD patients. All children had their weight, height, body mass
index (BMI) and Doppler blood pressure measured; these were
expressed as standard deviation score (SDS) for age and gender.
[23] Routine blood tests (including creatinine, calcium, ionized
calcium, phosphate, parathyroid hormone and serum urate) were
performed. All children above 5 years of age (n = 24 children on
dialysis [11 on PD, 13 on HD]; 14 children in pre-dialysis CKD
and 25 healthy controls) underwent vascular scans to assess carotid
artery intima media thickness (cIMT) and aortic pulse wave
velocity (PWV) using methods previously described [24] and
expressed as SDS for age. [25,26] Serum was obtained and ELISA
used to assess circulating levels of human Ang-1, Ang-2, VEGF-A,
Flt-1, E-selectin, P-selectin, intracellular adhesion molecule 1
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) (R &
D Systems). In some cases, serum samples were taken both pre-
and post- HD.
Immunolocalisation of Ang-1, Ang-2 and VEGF-A in intact
arteries
Medium-sized muscular arteries routinely removed at omen-
tectomy during a peritoneal dialysis catheter insertion or at renal
transplantation were obtained from some of the pre-dialysis CKD
and dialysis patients (n = 4 in each group). [3] Tissues were fixed in
formalin, embedded, then sections cut for immunohistochemistry
as described [27] for the following antibodies: rabbit anti-mouse
Ang-1 (ADI); rabbit anti-mouse Ang-2 (ADI); rabbit anti-human
VEGF-A (Santa Cruz) and rabbit anti-human von Willebrand
factor (DAKO). Intensity of staining was quantified by a blinded
observed and scored between 0 (no reactivity) to 3 (strong
staining); at least four images were obtained from each vessel and a
mean value obtained for each specimen.
Uric acid stimulation of human umbilical vein endothelial
(HUVEC) and aortic smooth muscle cells (HAoSMC)
HUVEC and HAoSMC (Lonza) were cultured in either EGM-
MV or DMEM supplemented with 20% FBS, 25 mM HEPES,
100 U/ml penicillin and 100 mg/ml streptomycin respectively.
Cells from passage 2–4 were grown to 70% confluence, placed in
low-serum media for 24 hours and challenged with varying
concentrations of uric acid (3–12 mg/dl) [28] for 15 minutes,
24 hours and 72 hours. Conditioned media was collected at all
time-points to assess Ang-2 levels and cell lysates extracted for
protein measurements. In other experiments, RNA was extracted
from cells stimulated with uric acid for 6 hours and used for RT-
PCR for Ang1, Ang2, organic anion transporters 1–4 (Oat1-4) Tie1,
Tie2, Toll-like receptor 4 (Tlr4) and human uric acid transporter 1
(Urat1) using previously described methods. [28] Quantitative RT-
PCR was also performed for Ang2 on HUVEC exposed to uric
acid (n = 3 for each dose) with hypoxanthine-guanine phosphor-
ibosyltransferase (HPRT) used as a house-keeping gene. Primer
details available on request.
Statistics. Results are presented as mean 6 SD or median
and inter quartile range (IQR), depending on the distribution.
Univariate comparisons of continuous variables were performed
using unpaired t-test for normally distributed data, or non-
parametric Mann-Whitney U-test for non-normally distributed
variables. For multiple comparisons of several groups, ANOVA or
Kruskall-Wallis test were performed. Within group comparisons of
continuous variables were performed using paired t-test or
Wilcoxon test, as appropriate. Spearman tests were used for
correlation analyses. Interactions between Ang-2 and biochemical
data or vascular scans were tested by two way ANOVA and the
difference between each pair of means compared by Tukey’s test
with appropriate adjustment for the multiple testing. Factors
affecting the two outcome variables, Ang-2 and cIMT, were
explored using multiple regression analysis, including all variables
with p #0.15 from univariate analysis in the stepwise multiple
regression models. For all analyses, p ,0.05 was considered
statistically significant.
Results
Circulating Ang levels in pre-dialysis CKD and dialysis
patients
Demographic and clinical parameters of the groups studied are
summarized in Table 1. The pre-dialysis CKD and dialysis
patients were similar in all demographic, clinical and biochemical
markers except that 25-hydroxyvitamin D was lower and serum
cholesterol and urinary albumin/creatinine ratio higher in dialysis
patients (Table 1). The healthy controls had significantly higher
BMI SDS and lower blood pressure SDS and urate levels versus the
patients.
Ang-1 levels were modestly but significantly (p = 0.02) lower in
pre-dialysis CKD patients compared with healthy controls
(respective means6SD being 2.961.8 and 4.361.8 ng/ml). In
dialysis patients, Ang-1 levels (mean6SD 5.063.5 ng/ml) were
similar to values found in healthy controls. Circulating Ang-2
levels were not significantly different between healthy children and
those with pre-dialysis CKD, but were markedly and significantly
increased in the dialysis group (means6SD in controls 2.761.2,
pre-dialysis CKD 2.760.9, dialysis 10.566.9 ng/ml, p,0.0005 in
comparisons between dialysis patients and both the other groups).
As explained in the Introduction, Ang-2 acts an endogenous
antagonist to Ang-1, such that comparative levels may be relevant;
hence we evaluated the Ang-2/Ang-1 ratio. There was no
difference in the Ang-2/Ang-1 ratios (Figure 1C) between control
Angiopoietin-2 in Children with CKD
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and pre-dialysis CKD individuals but it was significantly higher in
dialysis patients compared with the other groups (means6SD in
controls 0.860.7, pre-dialysis CKD patients 1.260.7 and dialysis
patients 2.561.4 ng/ml, p,0.0005 in comparisons between
dialysis and both the other groups)
Correlation of Ang levels with clinical and vascular
measures
Ang-2 levels had no significant relation to age or gender, but
increased linearly with time on dialysis (r = 0.37, p = 0.002)
whereas there was no association of Ang-2 levels with the time
spent in pre-dialysis CKD (p= 0.8, Figure 2A). There was no
Table 1. Demographic, clinical, anthropometric, and biochemical characteristics of patients and control subjects.
Characteristics Pre-dialysis CKD (n=20) Dialysis (n =30) Healthy Controls (n=25) p
Age (yr) 10.764.1 14.263.9 13.162.8 0.68
Sex (males/females) 12/8 17/13 14/11 0.82
Race (White/Asian/Black/other) 14/5/1/0 19/7/2/2 16/7/2/0 0.85
eGFR (ml/min per 1.73 m2) 18.366.0 - 11369.8 -
Time in CKD4-5 pre-dialysis (yr; median [IQR]) 4.5 (1.1–9.2) 3.9 (0.2–7.9) - 0.70
Time on dialysis (yr; median [IQR]) - 1.4 (0.2–3.9) - -
Dialysis modality (PD/HD) - 14/16 - -
BMI SDS 20.661.1 20.760.3 1.160.7 0.42
Systolic BP index* 1.960.8 1.562.5 0.860.2 0.21
Numbers on antihypertensive medications 11 4 0 0.6
Numbers on ACEi or ARB 4 0 0 0.1
Hemoglobin (g/dl) 12.361.9 11.460.8 12.160.9 0.51
Albumin (g/L) 39.064.1 4164.8 4060.6 0.34
Total cholesterol (mmol/L) 3.561.3 4.160.9 3.160.7 0.07
Triglycerides (mmol/L) 1.160.7 1.462.1 0.960.6 0.11
No. on statins 0 1 0 -
Albumin-adjusted calcium (mmol/L) 2.460.2 2.460.1 2.460.2 0.9
Serum phosphate levels (mmol/L) 1.460.6 1.660.8 1.260.2 0.9
Parathyroid hormone (pmol/L) 5.261.1 8.963.7 - 0.06
Serum urate level ( mmol/L) 260620.8 278629.3 184633.0 0.88
25-hydroxyvitamin D (nmol/L) 40.1616.2 12.969.8 - 0.04
Urinary albumin / creatinine ratio (mg/mmol) 122.8618.6 260.0664.3 (n = 21) - 0.04
All values are presented as mean6SD; p value indicates comparisons between the pre-dialysis CKD and dialysis groups. Parathyroid hormone, 25-hydroxyvitamin D and
urinary albumin / creatinine ratio were not measured in healthy controls due to small volumes of serum and lack of urine samples. * Systolic BP index = measured BP/
95th centile BP for age, gender, and height. ARB, angiotensin II receptor blocker; ACEi, angiotensin-converting enzyme inhibitor; BMI, body mass index; SBP, systolic BP;
SDS, SD score.
doi:10.1371/journal.pone.0056273.t001
Figure 1. Circulating Ang levels in pre-dialysis CKD and dialysis patients. Serum Ang-1 levels (A) were significantly lower in pre-dialysis CKD
patients compared with healthy controls. In dialysis patients Ang-1 levels were similar to values found in healthy controls. Similar levels of both
circulating Ang-2 (B) and Ang-2/Ang-1 (C) were found in healthy children and those with pre-dialysis CKD, but these were significantly increased in
the dialysis group.
doi:10.1371/journal.pone.0056273.g001
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difference in Ang-2 levels between HD and PD patients.
Circulating Ang-2 levels was also not significantly related to the
presence of residual renal function. To determine whether Ang-2
was cleared by HD, we obtained serum samples pre- and post-HD
from 5 individuals. There was no significant differences in Ang-2
levels (means6SD 5.061.1 and 4.660.9 ng/ml, p= 0.7).
Serum urate levels were significantly increased in both pre-
dialysis CKD and dialysis patients compared with controls
(Table 1) and showed a weak positive correlation with systolic
blood pressure SDS in these patients (r = 0.12, p = 0.048). Urate
levels positively correlated with Ang-2 levels in the dialysis group
(r = 0.52, p= 0.004, Figure 2B). There was a strong positive
correlation between Ang-2 levels and systolic blood pressure SDS
in the dialysis patients (r = 0.64, p= 0.003), but not in the pre-
dialysis CKD group, Figure 2C). No significant correlations were
found between Ang-1 or Ang-2/Ang-1 ratio with any clinical,
biochemical or vascular parameters.
Three out of 14 (21%) pre-dialysis CKD patients had increased
cIMT compared with age-matched controls (0.3760.03 versus
0.3860.02 mm respectively), but there was no significant corre-
lation between Ang-2 and cIMT in this group (p = 0.82,
Figure 2D). In contrast, cIMT was increased in 16 of 24 (66%)
dialysis patients (0.4660.05 mm) and showed a strong positive
correlation with Ang-2 (r = 0.62, p = 0.0005, Figure 2D). PWV
was increased in two out of 14 children with pre-dialysis CKD
(5.160.2 m/sec in pre-dialysis CKD versus 5.060.3 m/sec in
controls) and 7 out of 24 (5.660.5 m/sec) on dialysis but did not
show any correlation with Ang-2 in either group. Ang-2 levels
were not significantly correlated with blood cholesterol, triglycer-
ide, albumin, calcium, phosphate, parathyroid hormone, 25-
hydroxyvitamin D or urinary albumin/creatinine levels in pre-
dialysis CKD or dialysis patients. On multiple regression analysis
the significant determinants of Ang-2 levels were systolic blood
pressure and serum urate levels (Table 2). Carotid IMT was
significantly and independently influenced by the time on dialysis,
calcium x phosphate product and Ang-2 levels (Table 2).
Circulating levels of VEGF-A and sFlt-1
The biological actions of Ang-2 on blood vessels are dependent
on VEGF-A availability; [14] so we measured circulating levels of
this growth factor and the endogenous VEGF-A inhibitor, sFlt-1.
Ang-2 levels were similar in healthy controls and pre-dialysis CKD
patients and therefore VEGF-A and sFlt-1 levels were only
measured in pre-dialysis CKD and dialysis patients. VEGF-A
levels were significantly lower in individuals on dialysis compared
with pre-dialysis CKD patients (respective medians being 6.9 and
33.5 pg/ml, p = 0.003, Figure 3A). In contrast, sFlt-1 levels were
significantly higher in dialysis patients compared with pre-dialysis
CKD (respective means6SD of 222678 and 121654 pg/ml
respectively, p,0.0001, Figure 3B). There were no significant
Figure 2. Correlation of Ang-2 levels with clinical and vascular parameters. Ang-2 levels in dialysis individuals correlated positively with
time on dialysis (A), serum urate levels (B), systolic blood pressure SDS (C) and cIMT (D). Independent variables are shown on the x-axis. Regression
lines account for dialysis patients only. Dotted line in D indicates the value for cIMT in healthy age-matched controls. There was no correlation
between Ang-2 and any clinical and vascular measures in pre-dialysis CKD patients.
doi:10.1371/journal.pone.0056273.g002
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correlations of either VEGF-A or sFlt-1with time or mode of
dialysis, urate levels, blood pressure SDS or any other vascular
measures.
Circulating levels of soluble cell adhesion molecules
Ang-2 has been shown to have pro-inflammatory actions.
[16,17] Therefore, circulating levels of cell adhesion molecules
which attract inflammatory cells were measured. [29] Compared
with pre-dialysis CKD individuals, patients treated with dialysis
had significantly elevated levels of soluble E-selectin (respective
means6SD being 72631 and 54621 ng/ml, p = 0.03,
Figure 4A), soluble P-selectin (75627 versus 52617 ng/ml,
p = 0.001, Figure 4B) and soluble VCAM-1 (1.960.5 versus
1.360.4 mg/ml, p,0.0001, Figure 4C) but there was no
difference in ICAM-1 (354699 versus 341691 ng/ml,
Figure 4D). In the dialysis population, circulating levels of Ang-
2 positively correlated with soluble VCAM-1 (r = 0.41, p = 0.02),
but there were no significant correlations with E-selectin, ICAM-1
or P-selectin.
Immunolocalisation of vascular growth factors in arteries
To seek potential source(s) of Ang-1, Ang-2 and VEGF-A
immunohistochemistry was undertaken on intact arteries obtained
from a subset of the pre-dialysis CKD and dialysis patients. [3]
Ang-1 protein was detected in the media of vessels from pre-
dialysis CKD (Figure 5A) and dialysis patients (Figure 5B). As
scored by an observer blinded to the source of the samples, there
was no difference in staining intensity between the two groups
(Figure 5C). Ang-2 was also immunodetected in the media of
both pre-dialysis CKD (Figure 5D) and dialysis (Figure 5E)
vessels with a similar intensity in each group (Figure 5F). Ang-2
expression was also detected in the endothelial layer which was
also positive for von Willebrand factor (Figure 5G, 5H). VEGF-A
immunostaining was prominent in the media of pre-dialysis CKD
vessels (Figure 5I), but was significantly decreased in dialysis
patients (Figure 5J and K).
Effect of uric acid exposure on Ang-2 release in-vitro
As demonstrated above, Ang-2 levels strongly and positively
correlated with urate levels in dialysis patients. We hypothesized
that elevated urate might increase Ang-2 expression by, and/or
release from, endothelial and/or vascular smooth muscle cells.
There has been a previous report that uric acid can stimulate
release of contents from Weibel-Palade bodies including Ang-2.
[13] We first examined how urate may enter HUVEC and
detected the urate transporter, Urat1, but not Oat1-4; the mRNA
levels of Urat1 showed a tendency to decrease with increasing doses
of uric acid stimulation (Figure 6A). HUVEC also expressed Ang-
1, Ang-2, Tie-1 and Tie-2 (Figure 6A).
Exposure of HUVECs to uric acid for 15 minutes led to an
increase in Ang-2 release versus control media as evaluated by the
proportion of Ang-2 protein in the conditioned media. The most
prominent response was observed with 12 mg/dl with Ang-2 levels
significantly elevated compared with all other groups (Figure 6B).
This was an acute effect because longer term stimulation with uric
acid for 72 hours did not enhance the release of Ang-2 protein in
the conditioned media (Figure 6C). Within the cells, uric acid
Table 2. Multiple regression analyses for independent
predictors of Angiopoietin-2 (Ang2) and carotid intima media
thickness (cIMT).
Variables b SE p Model R2
Ang2 71%
Systolic BP 2.54 0.21 ,0.001
Serum urate level 0.14 0.006 0.03
cIMT 68%
Time on dialysis 0.50 0.02 0.008
Ca x P product 0.37 0.12 0.02
Ang2 0.26 0.06 0.05
b - Unstandardized regression coefficient; indicates the difference in the
outcome variable (Ang2 or cIMT) per unit change in the independent variables.
SE – standard error
Model R2 - The amount of variance in the dependent variable that can be
explained by the model.
doi:10.1371/journal.pone.0056273.t002
Figure 3. Circulating levels of VEGF-A and sFlt-1 in pre-dialysis CKD and dialysis patients. VEGF-A levels were significantly lower in
individuals on dialysis compared with pre-dialysis CKD patients (A). In contrast, sFlt-1 were significantly higher in the dialysis patients (B)
doi:10.1371/journal.pone.0056273.g003
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stimulation led to a decreased abundance of Ang-2 mRNA after
6 hours of stimulation (Figure 6D), compared with controls. It
has been suggested that the acute release of Ang-2 from endothelia
is mediated by Tlr4 [13] and we detected mRNA levels of Tlr4 on
HUVECs (Figure 6A). Prior studies have shown that HAoSMC
express the Urat1 receptor [28] and in the current study they were
also found to express transcripts for Ang-1, Ang-2 and Tie-2, but not
Tie-1 (data not shown); however, we did not detect Ang-2 protein
in the conditioned media with/without addition of uric acid.
Discussion
Our study demonstrated that circulating Ang-2 levels were
markedly elevated in dialysis patients compared with healthy
controls and pre-dialysis CKD individuals. Amongst the dialysis
patients, Ang-2 positively correlated with time on dialysis, systolic
blood pressure and cIMT, but not PWV. These findings may
indicate that circulating Ang-2 is a marker for the early
cardiovascular changes occurring in children with CKD on
dialysis. Previous studies have demonstrated that in the more
compliant vessels of children with CKD structural changes
precede functional alterations with increases in cIMT observed
before alterations in PWV. [30] Furthermore, our work examining
intact vessels from children on dialysis indicated that the vessel
calcium load showed a strong linear association with cIMT but not
with PWV or the coronary calcification score. [3]
Our findings concur with several studies that have shown a
relationship between circulating Ang-2 levels and cardiovascular
complications in adults. Elevated circulating Ang-2 is associated
with scores for coronary and peripheral arterial disease in adults
with CKD on PD or HD [20] and positively correlated with
systolic blood pressure and left ventricular hypertrophy in 4000
young to middle-aged individuals. [31]. A further study [21]
demonstrated that Ang-2 was an independent predictor of
mortality in CKD patients and correlated with markers of vascular
disease (cholesterol, hsCRP and osteoprotegerin) but not the
degree of vascular calcification or arterial stiffness. The observa-
tion that circulating Ang-2 is also elevated in children on dialysis
suggests that the uraemic environment may directly influence
vascular growth factor expression. This is because children do not
have many of the cardiovascular comorbidities that are commonly
seen in adults. In addition, the pathophysiology of CVD in
children may be different to that found in adults, for example, our
Figure 4. Circulating levels of soluble cell adhesion molecules. Compared with pre-dialysis CKD individuals, patients treated with dialysis had
significantly elevated levels of soluble E-selectin (A), P-selectin (B) and VCAM-1 (C); there was no difference in ICAM-1 levels (D).
doi:10.1371/journal.pone.0056273.g004
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previous work has shown that children on dialysis develop
arteriosclerosis with exclusively medial involvement [3] whereas
adults are much more likely to have both intimal lesions as well as
medial damage [32]. Therefore results from adults may not be
able to be directly extrapolated to the paediatric population and
studies in children with CKD are necessary.
Our studies found that the elevation in circulating Ang-2 levels
were similar immediately before and after a HD session. Both
Ang-1 and Ang-2 form multimeric structures composed of
monomers of 55 kDa [33] and therefore unlikely to be affected
by dialytic clearance. In contrast to adults with CKD [19,21] we
did not detect different Ang-2 levels in children with pre-dialysis
CKD compared with healthy controls. One explanation for this
Figure 5. Immunolocalisation of vascular growth factors in arteries. Ang-1 was detected in the media of vessels from both pre-dialysis CKD
(A) and dialysis patients (B); no differences in staining intensity were observed between the two groups (C). Ang-2 was immunodetected in both the
media and endothelia (arrows) in pre-dialysis CKD (D) and dialysis (E) vessels with similar intensity (F). The endothelial later was also positive for von
Willebrand factor (arrows, G and H). VEGF-A immunostaining was prominent in the media of pre-dialysis CKD vessels (I), but was significantly
decreased in dialysis patients (J and K). All fields taken with640 objective.
doi:10.1371/journal.pone.0056273.g005
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discrepancy could be that the children under study had not been
exposed to diabetes mellitus, and that dyslipidaemia and
hypertension were less common than in adults with CKD. Indeed,
each of these factors have been shown to be associated with
elevated Ang-2. [31,34] Instead, children with pre-dialysis CKD
had decreased circulating Ang-1 compared with healthy controls.
This loss of Ang-1 in pre-dialysis CKD children may decrease
blood vessels stability and be an early sign of the endothelial
dysfunction which occurs in these patients. [9] Potential sources of
Ang-1 not only include the vessel wall, but also platelets [35] and
one caveat to consider when measuring circulating Ang-1 in serum
samples is that ex-vivo activation may increase Ang-1 levels within
serum tubes. [36] In future studies, it would be of interest to
quantify both circulating Ang-1 and platelet-derived Ang-1.
Elevated circulating Ang-2 levels in dialysis versus non-dialysis
CKD children were associated with an anti-angiogenic environ-
ment as demonstrated by decreased circulating VEGF-A and
elevated soluble sFlt-1 (Table 3). Increased sFlt-1 [37] and
reduced circulating VEGF-A [38] have been demonstrated in
adult populations with CKD. In the presence of low VEGF-A,
Ang-2 will destabilise blood vessels leading to vessel regression.
[14] This milieu of growth factors may therefore contribute to the
impaired endothelial function seen in CKD children on dialysis.
[9,39]
Increased circulating Ang-2 in CKD children on dialysis was
also associated with pro-inflammatory responses with high urate,
E-selectin, P-selectin and VCAM-1 (Table 3). Systemic inflam-
mation is seen in children with CKD with dialysis [3,40] and Ang-
2 may play a direct role in this process. Ang-2 can sensitise the
endothelium to inflammatory responses; [16] and directly affect
the biology of inflammatory cells which express the Tie-2 receptor
themselves. [41,42] Although, we demonstrated that Ang-2/Ang-1
was also elevated in CKD children on dialysis it did not correlate
with any cardiovascular parameters. This suggests that the total
Ang-2 levels are important in biological responses in dialysis
patients, rather than the relative balance between Ang-2 and Ang-
1.
We detected Ang-2 in the endothelium of intact arteries isolated
from children with CKD and cultured HUVECs indicating this
cell type is a potential source of the increased Ang-2 in dialysis
patients. Our studies detected Ang-2 in the walls of intact arteries
from both pre-dialysis CKD and dialysis patients and Ang-2
transcripts were detected in cultured HoASMCs. Using Ang-2/
LacZ mice positive expression in renal arterial walls during kidney
development has been observed; [43] whilst Ang-2 has been
detected in cultured mouse embryonic fibroblasts [44] and smooth
muscle cells derived from the heart microvasculature. [45] We
could not detect any Ang-2 released from HoASMCs suggesting
Figure 6. Effect of uric acid on Ang-2 secretion in HUVECs. A) Both non-stimulated and uric acid stimulated HUVECs expressed the mRNA for
the transporter Urat1 but not Oat1-4; they were also positive for Ang-1, Ang-2, Tie-1, Tie-2 and Tlr4. Sizes were determined using a 100 bp marker (m),
positive (+ive) controls consisted of total kidney cDNA and negative controls were without cDNA addition. (B) Uric acid stimulation for 15 minutes,
but not 72 hours (C) led to elevated Ang-2 secretion in the conditioned media of HUVEC cells. Within the cells, uric acid stimulation led to a
decreased abundance of Ang-2 mRNA after 6 hours of stimulation (D). a = p,0.05 compared with controls, b = p,0.01 compared with controls,
c = p,0.001 compared with controls, d = p,0.01 compared with HUVEC stimulated with 3 mg/dl uric acid, e =p,0.01 compared with HUVEC
stimulated with 6 mg/dl uric acid, f = p,0.05 compared with HUVEC stimulated with 9 mg/dl uric acid.
doi:10.1371/journal.pone.0056273.g006
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vascular smooth muscle cells may not contribute to the increase in
Ang-2 seen in dialysis patients. We cannot rule this out completely
as the cells used in these experiments were not derived from
patients, nor did we reproduce the uremic milieu they will be
exposed to in-vivo. Another potential source of Ang-2 are
macrophages. [41,46] Although prior studies [3] have demon-
strated that macrophages are not present in the intact arteries of
children on dialysis they may be found in the circulation and
increase Ang-2.
There are several potential mechanisms for the increase in
circulating Ang-2 in patients with CKD. The increase in Ang-2
may be a direct consequence of elevated blood pressure. Korff and
colleagues [47] demonstrated that hypertension in mice led to
release of stored Ang-2 from Weibel-Palade bodies. There is also
evidence that mediators of vascular tone such as angiotensin II can
directly alter Ang-2 expression. [48] A lack of endothelial nitric
oxide may also predispose to a release of Weibel-Palade bodies
that would theoretically increase Ang-2 levels. [49]
One potential factor that could bring these various mechanisms
together is uric acid. Urate is retained in CKD and found to
correlate with Ang-2 levels in the dialysis patients. We showed that
uric acid could directly induce the release of Ang-2 from HUVEC
with a corresponding decrease in mRNA abundance within the
cell, consistent with prior reports that uric acid stimulates release
of Weibel-Palade bodies. [13] These effects are likely to be
mediated by Urat1 and Tlr4 [13], both of which were found to be
expressed on endothelia. Future studies using inhibitors specific for
Urat1 (probenecid [28] and Tlr4 (TAK-242 [50] would help to
determine the specific role of these molecules in Ang-2 release
from endothelia exposed to uric acid. In addition, there is
increasing evidence that urate may have a role in hypertension via
effects that include inducing endothelial dysfunction, oxidative
stress and the production of angiotensin II. [51] These findings
might account for why urate can contribute to cardiovascular
complications. [52,53]
In conclusion, Ang-2 is a marker for cardiovascular disease in
children on chronic dialysis. Furthermore, we suggest that Ang-2
may also be an anti-angiogenic and pro-inflammatory effector in
this context.
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